Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Petrioli, Roberto; Pozzessere, Daniele; Messinese, Simona; Sabatino, Marianna; Palma, Teresa; Marsili, Stefania; Correale, Pierpaolo; Manganelli, Antonio; Salvestrini, Francesco; Francini, Guido

doi:10.1159/000070285

Cited by 25 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Weekly administration of docetaxel has been shown to have similar efficacy with less neutropenia than 3-weekly schedules [15]. Several phase II studies in CRPC have investigated weekly docetaxel, given at doses of 25–40 mg/m 2 in a variety of schedules [16,17,18]. …”

Section: Discussionmentioning

confidence: 99%

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

Shamseddine

Farhat²,

Elias³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Introduction: Docetaxel has become the standard chemotherapy for patients with castration-resistant prostate cancer (CRPC). We wanted to assess the efficacy and safety of a weekly high-dose calcitriol, docetaxel and zoledronic acid combination in CRPC. Patients and Methods: Thirty patients were enrolled to receive calcitriol 0.5 µg/kg orally in 4 divided doses over 4 h on day 1 of each treatment week, docetaxel 36 mg/m² i.v. infusion on day 2 of each treatment week and zoledronic acid 4 mg i.v. on day 2 of the first and fifth week of each cycle. Treatment was administered weekly for 6 consecutive weeks on an 8-week cycle. Results: Out of 23 evaluable patients, there was a response of prostate-specific antigen (PSA) in 11 patients (47.8%); 6 (26.1%) had a stable PSA level for a median of 4.2 months. The median survival time was 15 months (95% confidence interval 13.9–16.1 months). The regimen was generally tolerated; anemia was the only grade 3/4 hematological toxicity in 2 patients. Conclusions: This regimen was tolerated, and half of the patients had a PSA response. Although our response rates are inferior to some studies using docetaxel, we believe our response rates are acceptable knowing that we are treating CRPC, which still has variable outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

Shamseddine

Farhat²,

Elias³

et al. 2012

Urol Int

View full text Add to dashboard Cite

show abstract

“…This indicates that tolerability of the present protocol is acceptable in a population that is often elderly. The major contribution of the chemotherapy in HRPC is improvement in the quality of life, particularly with respect to pain relief [3, 4, 18]. Beer et al [14]have previously reported that docetaxel alone helped to improve pain significantly.…”

Section: Discussionmentioning

confidence: 99%

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Ferrero¹,

Foa²,

Thézenas³

et al. 2004

Oncology

View full text Add to dashboard Cite

Rationale: Docetaxel has proven its efficacy in the management of hormone-refractory prostate cancer (HRPC). Schedules of docetaxel administration differ. This prospective phase II study was designed to reevaluate the activity and toxicity of docetaxel administered weekly at an optimal dose to a large cohort of HRPC patients. Patients and Methods: Sixty-four patients were treated with docetaxel 40 mg/m² i.v., administered weekly for 6 consecutive weeks followed by a 2-week recovery period. Three treatment cycles were planned in the absence of progression or toxicity. The principal end point was the biochemical response based on the prostate-specific antigen (PSA) level (a decline of more than 50% for at least 4 weeks). Secondary end points were objective response to measurable disease, survival and toxicity. Results: Toxicity was assessed in 64 patients. Toxicity was acceptable, with no toxicity-related deaths. Twenty-one percent of the patients developed grade 3–4 hematological toxicity. Sixty-four patients were evaluable for the PSA response. Forty-one patients (64%) achieved a decrease in PSA of >50%, 13 of whom had a PSA <4 ng/ml. Two out of 12 patients with measurable disease exhibited an objective response. With respect to PSA, the median progression-free survival was 29 weeks (95% confidence interval: 18–46 weeks). The global 1-year survival rate was 58%. Conclusion: Weekly docetaxel at a dosage of 40 mg/m² is a well-tolerated treatment, which has very promising activity on the reduction of PSA in metastatic HRPC. A large phase III study is underway.

show abstract

“…Reason for exclusion Mattioli (1998) 189 Not an RCT MedlinePlus (2005) 190 Background Miller (2002) 191 Not an RCT Miller (2003) 192 Not an RCT Montero (2005) 193 Background Moore (1994) 194 Not an RCT Muthuramalingam (2004) 9 Background Nabhan (2005) 195 Background National Cancer Institute (1999) 196Background National Institute for Clinical Excellence (2002) 8 Background Newling (1999) 225 Commentary/overview Office for National Statistics (2002) 3 Background Oh (2000) 226 Commentary/overview Oh (1998) 227 Commentary/overview Olson (2000) 228 Commentary/overview Parmar (1998) 25 Background Parvez (2003) 229 Commentary/overview Petrioli (2003) 230 Not an RCT Petrylak (1999) 231 Commentary/overview Petrylak (2000) 232 Commentary/overview Petrylak (2000) 233 Not an RCT Petrylak (2002) 13 Background Petrylak (2002) 234 Commentary/overview Picus (1999) 235 Commentary/overview Picus (1999) 236 Not an RCT Pozzessere (2002) 237 Not an RCT Price (2004) 238 Commentary/overview Raghavan (2002) 239 Not an RCT Rago (2003) 240 Not an RCT Rajasenan (2001) 241 Not an RCT Rexer (2004) 242 Commentary/overview 244 Wrong patient group Rosenthal (2000) …”

Section: Study Detailsmentioning

confidence: 99%

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Collins¹,

Fenwick²,

Trowman³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for HealthResearch (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as ro...

show abstract

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Cited by 25 publications

References 18 publications

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Contact Info

Product

Resources

About